Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8421 Alone or in Combination in Advanced Solid Tumors (CYCAD-1)
NCT06188520Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of AZD8421 in breast cancer, ovarian cancer, sponsored by AstraZeneca. Started Dec 2023; status: active, not recruiting.
02
Drugs
AZD8421
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT06188520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188520.